Evaxion Biotech AS (EVAX) Actualités

Form F-3 - Registration statement by foreign private issuers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Evaxion to present at numerous upcoming conferences

Evaxion will provide company and scientific updates at conferences in both the US and Europe during the coming...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Evaxion announces closing of $10.8 million public offering

COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Evaxion announces pricing of $10.8 million public offering

COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage...

Form EFFECT - Notice of Effectiveness

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]